DCM Advisors’s Dr. Reddy's Laboratories RDY Stock Holding History

DCM Advisors’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-20,000	Closed	-$222K	–	210
2022 Q2	$222K	Buy	+20,000	New	+$217K	0.1%	175

Other funds holding RDY

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

DCM Advisors's RDY Position: Q3 2022 in Review

DCM Advisors sold out of Dr. Reddy's Laboratories (RDY) in Q3 2022, closing a stake of 20,000 shares — an estimated $222K sold.

DCM Advisors first reported a position in RDY in Q2 2022 and held it in 1 quarter. The position peaked at $222K in Q2 2022. 151 funds tracked by Wall St. Rank hold RDY as of Q3 2022.

DCM Advisors reported no remaining Dr. Reddy's Laboratories position as of Q3 2022 after selling out during the quarter.
DCM Advisors sold 20,000 Dr. Reddy's Laboratories shares in Q3 2022, an estimated $222K.
DCM Advisors first reported a position in Dr. Reddy's Laboratories in Q2 2022 and held it in 1 quarter.
DCM Advisors's Dr. Reddy's Laboratories position peaked at $222K in Q2 2022.
151 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2022.

Based on DCM Advisors's 13F filing for Q3 2022, filed 11 Sep 2023.